methergin 0,125 mg grageas
novartis de venezuela, s.a. - maleato de metilergometrina - gragea - 0,125 mg (a3)
methergin 0,2 mg/ml solucion inyectable
novartis de venezuela, s.a. - hidrogenomaleato de metilergometrina - solucion inyectable - 0,2 mg/ml ( a9)
signifor 0,3 mg / ml solucion inyectable
novartis de venezuela, s.a. - pasireotida diaspartato - solucion - 0,3 mg / ml
signifor 0,6 mg / ml solucion inyectable
novartis de venezuela, s.a. - pasireotida diaspartato - solucion - 0,6 mg / ml
signifor 0,9 mg / ml solucion inyectable
novartis de venezuela, s.a. - pasireotida diaspartato - solucion - 0,9 mg / ml
entresto 100 mg comprimidos recubiertos
novartis de venezuela, s.a. - sacubitrilo-valsartan - comprimidos recubiertos - 100 mg
entresto 200 mg comprimidos recubiertos
novartis de venezuela, s.a. - sacubitrilo-valsartan - comprimidos recubiertos - 200 mg
entresto 50 mg comprimidos recubiertos
novartis de venezuela, s.a. - sacubitrilo-valsartan - comprimidos recubiertos - 50 mg
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).
trileptal 6 % suspension oral
novartis de venezuela, s.a. - oxcarbazepina - suspensi - 6%